Boehringer Ingelheim Plans to Enter Medicare Drug Price Talks

Drugmaker Boehringer Ingelheim Pharmaceuticals Inc. is preparing to negotiate with Medicare on a price for its diabetes drug Jardiance, the company told Bloomberg Law Wednesday.

“We are committed to engaging in open and transparent conversations” with the Centers for Medicare & Medicaid Services, Boehringer Ingelheim wrote in an emailed statement. “We look forward to sharing detailed information with CMS on the value of Jardiance and to reinforce the need to invest in scientific medical innovation for the patients we serve.”

The Germany-based manufacturer, which shares Jardiance with Eli Lilly & Co., joins Bristol-Myers Squibb Co. and AstraZeneca Plc as companies ...